uniQure N.V. (NASDAQ:QURE – Get Free Report) CEO Matthew Kapusta sold 41,671 shares of the business’s stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $50.00, for a total value of $2,083,550.00. Following the completion of the sale, the chief executive officer directly owned 521,795 shares of the company’s stock, valued at approximately $26,089,750. This represents a 7.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
uniQure Stock Performance
Shares of QURE opened at $46.29 on Monday. uniQure N.V. has a 12-month low of $8.73 and a 12-month high of $71.50. The business’s fifty day moving average price is $24.74 and its 200 day moving average price is $22.17. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40. The stock has a market capitalization of $2.92 billion, a PE ratio of -13.30 and a beta of 0.98.
uniQure (NASDAQ:QURE – Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, topping the consensus estimate of ($0.88) by $0.03. The firm had revenue of $3.56 million for the quarter, compared to analyst estimates of $5.21 million. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. Equities research analysts forecast that uniQure N.V. will post -3.64 EPS for the current year.
Wall Street Analyst Weigh In
View Our Latest Stock Analysis on QURE
Institutional Investors Weigh In On uniQure
Institutional investors have recently added to or reduced their stakes in the company. Torren Management LLC acquired a new stake in shares of uniQure during the 4th quarter valued at about $28,000. Jones Financial Companies Lllp increased its position in uniQure by 509.0% in the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 509 shares during the period. IFP Advisors Inc acquired a new position in uniQure in the fourth quarter valued at approximately $48,000. Smartleaf Asset Management LLC bought a new position in shares of uniQure in the 4th quarter worth $48,000. Finally, CIBC Private Wealth Group LLC acquired a new position in shares of uniQure during the 3rd quarter worth about $50,000. 78.83% of the stock is owned by institutional investors and hedge funds.
About uniQure
uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.
Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.
See Also
- Five stocks we like better than uniQure
- SpaceX’s Historic IPO Has Already Sparked a 2X ETF Frenzy
- Cheesecake Factory Stock Is Up Over 50%—Is There Room for More CAKE?
- Royal Caribbean’s Best Quarter Ever Still Leaves a Big Question
- Lululemon’s China Backlash May Be Hiding a Bigger Valuation Story
Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.
